The stock's rise snapped a four-day losing streak.

Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the ...

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up ...

RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...

In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...

Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

DelveInsight's In Situ Hybridization Market Insights report provides the current and forecast market analysis, individual ...

The demand for in situ hybridization is experiencing significant growth, mainly due to the rising rates of cancer and genetic disorders. This trend is further driven by the increasing incidence ...

The global metagenomics market is set for significant expansion, fueled by technological advancements and growing applications in microbial research. According to a recent market research report by ...